IV drip chamber with a drop of liquid falling inside, next to the U.S. Food & Drug Administration (FDA) logo on a light background.
October 6, 2020

FDA Approves New Treatment for Mesothelioma Victims – SWMW Law | Mesothelioma & Asbestos Lawyers

Finally, some good news for those suffering from mesothelioma.

This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.

The new treatment combines Opdivo (nivolumab) and Yervoy (ipilimumab), which has shown improvement in patients with mesothelioma when it cannot be removed by surgery. Such advancements in the fight against mesothelioma haven’t been seen since 2004, giving encouragement to patients and caregivers alike.

“(The) approval of nivolumab plus ipilimumab provides a new treatment that has demonstrated an improvement in overall survival for patients with malignant pleural mesothelioma,” said Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence. “In 2004, the FDA approved pemetrexed in combination with cisplatin for this indication, and now patients now have an important, additional treatment option after more than a decade with only one FDA-approved drug regimen.”

During a clinical trial, 605 patients with untreated mesothelioma participated in a randomized, open-label trial to determine if the treatment would improve survival rates when compared to chemotherapy.

Patients received intravenous infusions of Opdivo every two weeks and Yervoy every six weeks for up to two years, or platinum-doublet chemotherapy for up to six cycles. Treatment was administered until the disease progressed or unacceptable levels of toxicity were reached.

Patients who received the drug combination treatment had a median survival rate of 18.1 months, compared to a median of 14.1 months for those who underwent chemotherapy treatment. The finding potentially gives victims and their families a priceless gift – more time.